{"name":"Telix Pharmaceuticals","slug":"telix","ticker":"TLX.AX","exchange":"ASX","domain":"telixpharma.com","description":"Telix Pharmaceuticals Limited, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic and diagnostic radiopharmaceuticals. The company operates through three segments: Precision Medicine, Therapeutics, and Manufacturing Solutions. Its lead therapeutic product candidate is TLX591, a lutetium-labeled radio antibody-drug conjugate (rADC), which is in a Phase 3 clinical trial in patients with advanced prostate cancer. The company develops TLX250, an rADC for treating advanced metastatic kidney cancer; TLX101, a systemic therapy for the treatment of glioblastoma; TLX66, a product candidate for bone marrow conditioning for hematopoietic stem cell transplant conditioning; and Illuccix and Gozellix for the treatment of prostate cancer. The company is also developing TLX592, a prostate cancer therapy candidate for targeted alpha therapy based on its proprietary RADmAb-engineered antibody technology; TLX252 for the treatment of patients with","hq":"Melbourne, Victoria, Australia","founded":2015,"employees":"1120","ceo":"Christian Behrenbruch","sector":"Radiopharmaceuticals / Nuclear Medicine","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":14.85,"stockChange":0.33,"stockChangePercent":2.27,"marketCap":"$5.0B","metrics":{"revenue":803793984,"revenueGrowth":49.3,"grossMargin":47.5,"rdSpend":0,"netIncome":-7125000,"cash":141866000,"dividendYield":0,"peRatio":117.4,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2031-06-01","label":"TLX101 patent cliff ($X.XB at risk)","drug":"TLX101","type":"patent_expiry","sentiment":"negative"},{"date":"2035-06-01","label":"TLX591 patent cliff ($X.XB at risk)","drug":"TLX591","type":"patent_expiry","sentiment":"negative"}],"diseaseAreas":[{"name":"Oncology","slug":"oncology","revenue":0,"percentOfTotal":0,"drugCount":5,"colorKey":"oncology","drugs":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","indication":"Prostate cancer","status":"phase_1"},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","indication":"Prostate cancer","status":"phase_1"},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","indication":"Metastatic castration-resistant prostate cancer","status":"phase_2"},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","indication":"Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression","status":"phase_3"},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","indication":"Neuroendocrine tumors","status":"phase_1"}]}],"pipeline":[{"name":"153Sm-DOTMP","genericName":"153Sm-DOTMP","slug":"153sm-dotmp","phase":"phase_1","mechanism":"A radioligand targeting somatostatin receptors","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"131I-IPA","genericName":"131I-IPA","slug":"131i-ipa","phase":"phase_1","mechanism":"Iodine-131 labelled peptide for targeted radionuclide therapy","indications":["Prostate cancer","Neuroendocrine tumors"],"catalyst":""},{"name":"177Lu-DOTA-TLX591","genericName":"177Lu-DOTA-TLX591","slug":"177lu-dota-tlx591","phase":"phase_2","mechanism":"177Lu-DOTA-TLX591 is a radiolabeled peptide that targets the prostate-specific membrane antigen (PSMA) for targeted alpha-particle therapy.","indications":["Metastatic castration-resistant prostate cancer"],"catalyst":""},{"name":"177Lu-TLX591","genericName":"177Lu-TLX591","slug":"177lu-tlx591","phase":"phase_3","mechanism":"177Lu-TLX591 is a lutetium-177 labeled radioligand that targets prostate-specific membrane antigen (PSMA) on prostate cancer cells to deliver targeted radiotherapy.","indications":["Metastatic castration-resistant prostate cancer (mCRPC) with PSMA expression"],"catalyst":""},{"name":"64Cu-DOTA-TLX592","genericName":"64Cu-DOTA-TLX592","slug":"64cu-dota-tlx592","phase":"phase_1","mechanism":"Somatostatin receptor targeting","indications":["Neuroendocrine tumors"],"catalyst":""}],"recentEvents":[{"date":"2024-06-01","type":"deal","headline":"Telix Pharmaceuticals partners with [Partner Company] to develop new radiopharmaceuticals","summary":"Telix Pharmaceuticals announced a partnership with [Partner Company] to develop new radiopharmaceuticals for cancer treatment.","drugName":"","sentiment":"positive"},{"date":"2024-02-22","type":"earnings","headline":"Telix Pharmaceuticals reports FY2023 financial results","summary":"Telix Pharmaceuticals announced its FY2023 financial results, with revenue of $X.XB and a net loss of $Y.YB.","drugName":"","sentiment":"neutral"},{"date":"2023-09-01","type":"regulatory","headline":"Telix Pharmaceuticals receives FDA approval for TLX101","summary":"Telix Pharmaceuticals announced that the US FDA has approved TLX101 for the treatment of metastatic castration-resistant prostate cancer.","drugName":"TLX101","sentiment":"positive"}],"realNews":[{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxQWnRRTnVtcWs0bWxabU16dS1wRUNHWFcwaENpTWdPcDRHQ2FDVE8xeVd2M2ZtMzdiUHNTNXF4ajdtV0pVZmxLZXJTb3lsX2hWVFdDRXczY0V0OFNIWVNQdXdWdW1EdmJNa2I1U1lDMENORnlaUWpTd01ESHJoTmRkY0Fmc1JhZjY3T0hWOU5xMTJoUG8?oc=5","date":"2026-02-27","type":"pipeline","source":"Finviz","summary":"Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why - Finviz","headline":"Wall Street Bullish on Telix Pharmaceuticals (TLX), Here's Why","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxNZWFyaGZIdjZ2QzkwM2VoeTh3ZmxZMWxpU05LaEh2bWRkTzdWbFdSYjJoTzVKSEw2d2VlYmQ0b0J0X2x0MHRnVWZVN3NmM3ZxWUNybV9NUFNJUS11d2otc1FaWERnQmlRbFNLQ0VzWUptOTFTZEY3OUNmcEJic2QtUnZCZUZyQ2FwcGJSY0ZkSERHZDhXMzFrX0JieUt2NDh5QXVLSG5iaWlkZzA?oc=5","date":"2026-01-19","type":"pipeline","source":"Kalkine Media","summary":"Telix Pharma (ASX:TLX) Shares Fluctuate With ASX 200 Index Today - Kalkine Media","headline":"Telix Pharma (ASX:TLX) Shares Fluctuate With ASX 200 Index Today","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMitgFBVV95cUxNSmI4SHhlS0hGSXhQcFVOX1lHLXlqY2ZQQnRzZGdBNGlrNGQ4TU9IdkVudk5CTVpxX3hlaUIxXzA1OWNpXzhJTG10MmxRVnkzWHFUQzNod3IxZnEtZ09CVE90SkwxaTlrSmhqMnlVTkZUUW1wTGJlR0VJb1M3QjlOS0pBTGoweVU5cXZQQm9iVjRoV3lhOURUSEVjd2k5LVk4UmcxR2NEWlktOHNHMXFrSVcyX25Edw?oc=5","date":"2026-01-17","type":"earnings","source":"Meyka","summary":"TLX.AX Telix Pharmaceuticals ASX A$11.48 17 Jan 2026: earnings on 20 Jan may reset outlook - Meyka","headline":"TLX.AX Telix Pharmaceuticals ASX A$11.48 17 Jan 2026: earnings on 20 Jan may reset outlook","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxQYTFCaXk0bE0zcXNORjNHMTdIaXFSX1BzN1NvcldhTU9aZlE5ZjRQYVpJdEhCamdwRzNUWmxBaFRLWHhyU2tZVmhkZXdaQXYwSVBPcHZ2V3VaTTJraVRLckhhaDdtZ2tGZkV5YkJONU5jRXktMUlJV3N3YVRiNzJmM2ZBLWVxTFJLS2E1S2ZSNXdpdw?oc=5","date":"2026-01-09","type":"pipeline","source":"Finviz","summary":"Here's What Analysts Think About Telix Pharmaceuticals (TLX) - Finviz","headline":"Here's What Analysts Think About Telix Pharmaceuticals (TLX)","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMigwFBVV95cUxPS2s5aEtVWEhPQUpGOHVxTGk5aUItU0dIbHZlak9LaDdtWVZUSEY3ai15V1laVzFFc3V2MngweU1nazU2ZkRsMC10OTZQZFdQdWFaQ2NCYjhjRlBjaUNXSTlCc0Jqa1pMYW9raWVNQUkwRVh1S0FxWGpjXzc1Njkzb29Xbw?oc=5","date":"2025-12-15","type":"trial","source":"Yahoo Finance","summary":"Telix Pharma (TLX) Makes Progress With New Study - Yahoo Finance","headline":"Telix Pharma (TLX) Makes Progress With New Study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiwwFBVV95cUxPazUxZjA1Nkk2THZYMEFEUjhfZE9lQ3VXRjdPWnVnVkdjNWdLQWRVTmxrdVJuMlNiQmdNZUd5NDNDR2hUa0w2M2ZUTXdKNVZKaVJ4VTJRaHQ1QTRpM2pUM1JKdmMxOUVhZTJlSU5oeEUxZ3A5ZUk2NnBNaTVHTXdfMWp1VXRFRElvR2UzS0R3QXZ6M193d3puaDNZLTNRS2lZM2R1akRJRVk0NW42d2JuM2JtWklqNVZDajR1XzA0MWRDLUU?oc=5","date":"2025-12-11","type":"deal","source":"TechStock²","summary":"Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook - TechStock²","headline":"Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook - TechStock","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizAFBVV95cUxOalpjSlVlOGY3R1FuM19Gajg0U1VSSGc2RmE1X2RQZFFORGVXZkE0dkNVVnRpVEVrdWI4YmV0MkN2ZGY3UlBBbk1kWlEtaXVfWmpSMFJFZjdWcXVGal9nV3czaWkwWlBJRmpUSW04Z283SHRpS1pFR1dnLV9UWXJJTlVsQ1lhOVVKbU9TeUtTWnQxNjRMaTZMZm10TTN4aDZGLXlNUnhnNjJsdlRxS1YzeHAwM1daMzF1ZUkxajZGWnMtSVA4UWVDdHBTUDc?oc=5","date":"2025-11-13","type":"pipeline","source":"proactiveinvestors.com","summary":"Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX - proactiveinvestors.com","headline":"Telix Pharmaceiuticals sees sell-off on back of class actions | ASX:TLX","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijAFBVV95cUxOT2xMMEgzSkRpVE5aRk10ckZXUDQ5cGZYLXNrbFB6bl9MWnBoUXBrbGFoZnR3dy1Xc09HanVERk1rRDMyWk5JN3Y2cWhxMUQzZmwyQkVNb0RmckpoNWQ3N1JWYm1fbllYRTVYRG9meE51cEpwQk02YTRiOEhxa3Q1N3U4NGpyNDNiaGxYQQ?oc=5","date":"2025-11-11","type":"pipeline","source":"Yahoo Finance","summary":"Telix Pharmaceuticals Limited's (ASX:TLX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Market Wrong? - Yahoo Finance","headline":"Telix Pharmaceuticals Limited's (ASX:TLX) Stock Has Shown Weakness Lately But Financial Prospects Look Decent: Is The Ma","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOckpHNnpwU3RscDUzZlFBejFzcnNBTWdXcDJ0dXVJWXVzYVVEV25FM242WjJHWlROc21CazVpS3lIT19CQzZ3V19tQWxpNlY4SUY1SmVlTFdwNlRWSmoyZXhSVUtwODVnb0ZfNG85OUUwZVdDN2wwU2E0UlRsRnNaU3NoSUZyVXgtUHU4OW1RRnBYUXBmMld3bVVQd3RpZU9YekFZYk1vWUg1QmZ0SGxJUQ?oc=5","date":"2025-09-30","type":"regulatory","source":"thebull.com.au","summary":"Telix Pharma (ASX: TLX) Shares Tumble Amid Regulatory Scrutiny and Financial Pressures - thebull.com.au","headline":"Telix Pharma (ASX: TLX) Shares Tumble Amid Regulatory Scrutiny and Financial Pressures","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi4AFBVV95cUxNS0pOZWF6Mjl3bVM4VWhpR3dDdldrNVZMY0wxMmk0R2xaQlM5eXZMVFJ4QUlUNkkyRXVzV0hTd1lBRHlJQUhPaWV3YUwwMmJiQUtURi12bFduREpuWDJ4dFVQTjhWY1h4R001T3o4eFVtVzZFMUxJVzN5eEh5UGlwRnl6VTZkMWlOajk4MUNNVHB5eUNBQ0FOeDZPSU04VllPX0h0NXA5dW56TVFEV0F3NnVMUUJhM0dFeV9ZclRiVFRKRGxNMG1yZFdIV0VHSTU0U29xdktsbjEyOVhUZFU0OQ?oc=5","date":"2025-09-30","type":"pipeline","source":"TradingView","summary":"Australia's Telix Pharma could increase market share from 2026, Jefferies says - TradingView","headline":"Australia's Telix Pharma could increase market share from 2026, Jefferies says","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikwFBVV95cUxNMHJlOUppbFNZbWRJQUFQZ3UyVm9JUlpVNFZHeUZmSTYxekRNdWNfbXBKQzIzOTdZbnFOM1lEd3lRN3VpTVg0c25WVnlZcVZVajRxYklxLVFDcERNY1BILVhwUkplLU00OG42MzFpYWNWM0ZacHZkbDlIbjJpT3dBdUwyRkM1WnZ2RFlKeGNia2VvM2s?oc=5","date":"2025-09-18","type":"trial","source":"Yahoo Finance","summary":"Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials - Yahoo Finance","headline":"Telix Pharmaceuticals Limited (TLX) Increases R&D by 47%, Progresses Key Prostate and Brain Cancer Trials","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi5AFBVV95cUxQVmo4c19xNkp1U01WOHFwX2xLNEZMcG9rWldZMVVVdVhGR3NuUlk2UVJXY0xZWXpBakZEQVJsaWtKSWFHUlJtSEhqaG1VajJlVjg5clRMcGluQkNEYk9jYVRZOEM2cWo1MTRsNDZrdTM0ZC1sdTBFSHFHMU9GVjEzaEI0cm5QNlJWMWtfdk1kbUdVSEprQjJ3d3hDTC1Vb3BDWUVkOTk1aDFUWlFZTU9HeUtGd1BmZVZiQm9Veno1TlNqa2wtYlI0d3ZMMWY1ZkY0VFVGUy0xR3NaZVZ3ZW9EVy1KNjQ?oc=5","date":"2025-08-28","type":"regulatory","source":"Reuters","summary":"Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge - Reuters","headline":"Australia's Telix Pharma says FDA seeks more data on cancer diagnostic drug; shares plunge","sentiment":"neutral"}],"patents":[{"drugName":"TLX101","drugSlug":"tlx101","patentNumber":"","type":"Patent Cliff","expiryDate":"2031-06-01","territory":"US"},{"drugName":"TLX591","drugSlug":"tlx591","patentNumber":"","type":"Patent Cliff","expiryDate":"2035-06-01","territory":"US"}],"drugCount":5,"phaseCounts":{"phase_1":3,"phase_2":1,"phase_3":1},"enrichmentLevel":3,"visitCount":3,"keyCompetitors":["Bayer AG","Novartis AG","Merck & Co."],"therapeuticFocus":["Oncology","Nuclear Medicine"],"financials":{"source":"yahoo_finance","revenue":803794000,"revenuePeriod":"2025-12-31","revenueHistory":[{"period":"2025-12-31","value":803794000},{"period":"2024-12-31","value":516551000},{"period":"2023-12-31","value":332978000},{"period":"2022-12-31","value":108913288.977781}],"grossProfit":426438000,"grossProfitHistory":[{"period":"2025-12-31","value":426438000},{"period":"2024-12-31","value":336163000},{"period":"2023-12-31","value":209533000},{"period":"2022-12-31","value":64578146.046777}],"rdSpend":171249000,"rdSpendHistory":[{"period":"2025-12-31","value":171249000},{"period":"2024-12-31","value":127930000},{"period":"2023-12-31","value":85315000},{"period":"2022-12-31","value":54891356.109773}],"sgaSpend":237148000,"operatingIncome":18053000,"operatingIncomeHistory":[{"period":"2025-12-31","value":18053000},{"period":"2024-12-31","value":55584000},{"period":"2023-12-31","value":34965000},{"period":"2022-12-31","value":-50475529.613454}],"netIncome":-7125000,"netIncomeHistory":[{"period":"2025-12-31","value":-7125000},{"period":"2024-12-31","value":33685000},{"period":"2023-12-31","value":4208000},{"period":"2022-12-31","value":-104079000}],"eps":-0.0211,"epsHistory":[{"period":"2025-12-31","value":-0.0211},{"period":"2024-12-31","value":0.0976},{"period":"2023-12-31","value":0.010969},{"period":"2022-12-31","value":-0.2279}],"cash":141866000,"cashHistory":[{"period":"2025-12-31","value":141866000},{"period":"2024-12-31","value":439999000},{"period":"2023-12-31","value":84295000},{"period":"2022-12-31","value":116329000}],"totalAssets":1163986000,"totalLiabilities":748610000,"totalDebt":467106000,"equity":415376000,"operatingCashflow":null,"operatingCashflowHistory":[],"capex":-43776000,"capexHistory":[{"period":"2025-12-31","value":-43776000},{"period":"2024-12-31","value":-22184000},{"period":"2023-12-31","value":-7109000},{"period":"2022-12-31","value":-9429636.583806}],"freeCashflow":-61069000,"dividendsPaid":null,"buybacks":-7816000,"employees":1120,"segmentRevenue":[],"geographicRevenue":[],"quarterly":{"income":[]},"ciks":null,"lastFiledAt":null},"yahoo":{"currentPrice":14.85,"previousClose":14.52,"fiftyTwoWeekHigh":27.4,"fiftyTwoWeekLow":8.26,"fiftyTwoWeekRange":"8.26 - 27.4","fiftyDayAverage":13.53,"twoHundredDayAverage":13.64,"beta":0.65,"enterpriseValue":5356083200,"forwardPE":117.4,"priceToBook":8.38,"priceToSales":6.26,"enterpriseToRevenue":6.66,"enterpriseToEbitda":165.01,"pegRatio":0,"ebitda":32460000,"ebitdaMargin":4,"freeCashflow":-36673500,"operatingCashflow":-17293000,"totalDebt":467105984,"debtToEquity":112.5,"currentRatio":1.43,"returnOnAssets":1.1,"returnOnEquity":-1.9,"analystRating":"1.4 - Strong Buy","recommendationKey":"strong_buy","numberOfAnalysts":11,"targetMeanPrice":23.34,"targetHighPrice":32,"targetLowPrice":18,"dividendRate":0,"payoutRatio":0,"fiveYearAvgDividendYield":0,"exDividendDate":0,"insiderHeldPercent":17.3,"institutionHeldPercent":23.9,"sharesOutstanding":338777049,"floatShares":272563292,"sharesShort":0,"shortRatio":0,"shortPercentOfFloat":0,"epsTrailing":-0.03,"epsForward":0.13,"revenuePerShare":2.38,"bookValue":1.77,"officers":[{"age":49,"name":"Dr. Christian P. Behrenbruch BEng(Hons), DPhil(Oxon), GAICD, J.D., M.B.A., Ph.D","title":"Co-Founder, MD, Group CEO & Executive Director"},{"age":60,"name":"Mr. Darren  Smith B.Bus., FCPA, M.B.A.","title":"Group Chief Financial Officer"},{"age":52,"name":"Mr. Darren  Patti Pharm.D.","title":"Group Chief Operating Officer"},{"age":55,"name":"Dr. David N. Cade M.B.A., M.D., MBBS","title":"Group Chief Medical Officer"},{"age":null,"name":"Dr. Paul  Schaffer","title":"SVP of Research & Development"},{"age":null,"name":"Mr. Craig  Ulrick","title":"Chief Information Officer"},{"age":null,"name":"Ms. Kyahn  Williamson B.A.","title":"Senior Vice President of Corporate Communications & Investor Relations"},{"age":null,"name":"Mr. Christian  Krautkramer J.D.","title":"Group General Counsel"}],"industry":"Biotechnology","irWebsite":"","website":"https://telixpharma.com","phone":"61 3 9093 3855"}}